Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Market

The total incident population of Non-Small Cell Lung Cancer (NSCLC) in the seven major markets was 484,726 in 2017. The incident cases of ALK- positive mutation in the United states in 2017 was found to be 8,449.The United States accounts for around 38% of the total patient population of ALK-positive NSCLC among the 7MM.

The total market size of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) in the 7MM was USD 841 Million in 2017, which is expected to increase during the study period 2017-2030.

Some of the key companies in the ALK-NSCLC market include Pfizer, Takeda, Roche, Xcovery and many others.

For more detailed information visit: https://www.delveinsight.com/report-store/anaplastic-lymphoma-kinase-non-small-cell-lung-cancer-market